Chemomab to Participate in LifeSci Partners Annual Corporate Access Event and H.C. Wainwright BioConnect 2022 Healthcare Conference

Rhea-AI Summary

Chemomab Therapeutics, Ltd. (Nasdaq: CMMB) announced participation in two key virtual events: the LifeSci Partners 11th Annual Corporate Access Event from January 5-7, 2022, featuring 1-on-1 meetings, and the H.C. Wainwright BioConnect Conference from January 10-13, 2022, offering an on-demand corporate overview webcast. Chemomab focuses on therapeutics for fibrotic and inflammatory diseases, with its lead candidate, CM-101, in Phase 2 trials targeting multiple severe conditions. For event registration and additional details, visit Chemomab's website.

TEL AVIV, Israel, Dec. 20, 2021 /PRNewswire/ -- Chemomab Therapeutics, Ltd. (Nasdaq: CMMB) (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, today announced that senior management will participate in the LifeSci Partners 11^th Annual Corporate Access Event, which will be held virtually from January 5-7, 2022, and the H.C. Wainwright BioConnect Conference, which will be held virtually from January 10-13, 2022.

Event details are below:

LifeSci Partners 11^th Annual Corporate Access Event

Date:                 January 5-7, 2022
Format:            1-on-1 virtual meetings with senior management
Registration:    LifeSci Partners Corporate Access Event 2022

HC Wainwright BioConnect 2022 Virtual Healthcare Conference

Date:                 Webcast available on demand at 7:00am ET Jan.10 through Jan.13, 2022
Format:            Corporate overview webcast
Registration:    https://journey.ct.events/view/9e85b478-28c8-4b98-9959-d900bd47a369
Replay:             Available on Chemomab website starting Jan.14, 2022 at investors.chemomab.com/events

About Chemomab Therapeutics Ltd.
Chemomab is a clinical-stage biotechnology company focusing on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need. Based on the unique and pivotal role of the soluble protein CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a monoclonal antibody designed to bind and block CCL24 activity. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is currently in two Phase 2 safety and efficacy trials—one in patients with primary sclerosing cholangitis and the second in patients with liver fibrosis, with a third Phase 2 trial in systemic sclerosis expected to begin early in 2022.

For more information on Chemomab, visit chemomab.com.

Contacts:

Investor Relations:
Irina Koffler
LifeSci Advisors, LLC
Phone: +1-917-734-7387
ir@chemomab.com 

Media:
Barbara Lindheim
Chemomab Therapeutics
Consulting Vice President
Investor & Public Relations, Strategic Communications
barbara@chemomab.com 

View original content:https://www.prnewswire.com/news-releases/chemomab-to-participate-in-lifesci-partners-annual-corporate-access-event-and-hc-wainwright-bioconnect-2022-healthcare-conference-301448086.html

SOURCE ChemomAb Ltd.

FAQ

What events will Chemomab participate in January 2022?

Chemomab will participate in the LifeSci Partners 11th Annual Corporate Access Event from January 5-7, 2022, and the H.C. Wainwright BioConnect Conference from January 10-13, 2022.

What is CM-101 and its significance for Chemomab?

CM-101 is Chemomab's lead monoclonal antibody designed to treat fibrotic and inflammatory diseases. It is currently in two Phase 2 trials for severe conditions.

How can I register for the LifeSci Partners event?

Registration for the LifeSci Partners 11th Annual Corporate Access Event can be completed through their official link.

When will the H.C. Wainwright BioConnect Conference be available for viewing?

The H.C. Wainwright BioConnect Conference webcast will be available on demand from 7:00 AM ET on January 10 through January 13, 2022.

Where can I find more information about Chemomab's events?

More information regarding Chemomab’s events can be found on their official website under the investor relations section.